These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8822133)

  • 1. Sensitivity of experimental venous and arterial thrombosis and bleeding to ancrod-induced defibrinogenation.
    Schumacher WA; Heran CL; Steinbacher TE
    Thromb Res; 1996 Jan; 81(2):187-94. PubMed ID: 8822133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time.
    Schumacher WA; Heran CL; Steinbacher TE
    J Cardiovasc Pharmacol; 1996 Jul; 28(1):19-25. PubMed ID: 8797131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desmin 370, a low molecular weight dermatan sulfate, reduces the weight of preformed thrombi in rats made afibrinogenemic by ancrod.
    Barbanti M; Calanni F; Marchi E; Semeraro N; Colucci M
    Thromb Haemost; 1995 Feb; 73(2):287-90. PubMed ID: 7792745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857.
    Rübsamen K; Hornberger W; Kirchengast M
    Thromb Haemost; 1995 Nov; 74(5):1353-60. PubMed ID: 8607122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
    Schumacher WA; Steinbacher TE; Heran CL; Seiler SM; Michel IM; Ogletree ML
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1237-42. PubMed ID: 8263785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologic alteration of fibrinogen levels: influence upon patency of microvenous anastomoses.
    Cooley BC; Fowler JD; Gould JS
    Microsurgery; 1992; 13(6):299-303. PubMed ID: 1453930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo effect of a thrombin-like enzyme on platelet plug formation induced in mesenteric microvessels of mice.
    Chang MC; Huang TF
    Thromb Res; 1994 Jan; 73(1):31-8. PubMed ID: 8178311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defibrinogenating enzymes.
    Bell WR
    Drugs; 1997; 54 Suppl 3():18-30; discussion 30-1. PubMed ID: 9360849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin.
    Cercek B; Lew AS; Hod H; Yano J; Reddy NK; Ganz W
    Circulation; 1986 Sep; 74(3):583-7. PubMed ID: 3091287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic defibrinogenation by ancrod: effect on limb blood flow in peripheral vascular disease.
    Wiles PG; Nelson SR; Hampton KK; Casali B; Boothby M; Prentice CR
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):385-8. PubMed ID: 2133215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI study on delayed ancrod therapy of focal cerebral ischaemia in rats.
    Elger B; Hornberger W; Schwarz M; Seega J
    Eur J Pharmacol; 1997 Oct; 336(1):7-14. PubMed ID: 9384248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Pehrsson S; Johansson K; Kjaer M; Elg M
    Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis.
    Schumacher WA; Heran CL; Steinbacher TE; Youssef S; Ogletree ML
    J Cardiovasc Pharmacol; 1993 Oct; 22(4):526-33. PubMed ID: 7505353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program.
    Levy DE; del Zoppo GJ; Demaerschalk BM; Demchuk AM; Diener HC; Howard G; Kaste M; Pancioli AM; Ringelstein EB; Spatareanu C; Wasiewski WW
    Stroke; 2009 Dec; 40(12):3796-803. PubMed ID: 19875736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adhesion prevention with ancrod released via a tissue-adherent hydrogel.
    Chowdhury SM; Hubbell JA
    J Surg Res; 1996 Feb; 61(1):58-64. PubMed ID: 8769943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.
    Cho JH; Yun CH; Seo HS; Koga T; Dan T; Koo BA; Kim HY
    Thromb Haemost; 2001 Dec; 86(6):1512-20. PubMed ID: 11776321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ancrod enhances the thrombolytic effect of streptokinase and urokinase.
    Cercek B; Lew AS; Hod H; Yano J; Lewis B; Reddy KN; Ganz W
    Thromb Res; 1987 Aug; 47(4):417-26. PubMed ID: 3660351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinogen level as a surrogate for the outcome of thrombolytic therapy using tissue plasminogen activator for acute lower extremity intravascular thrombosis.
    Skeik N; Gits CC; Ehrenwald E; Cragg AH
    Vasc Endovascular Surg; 2013 Oct; 47(7):519-23. PubMed ID: 23899656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlling acute elevation of plasma fibrinogen with ancrod.
    Cole CW
    Cerebrovasc Dis; 1998 Jan; 8 Suppl 1():29-34. PubMed ID: 9547026
    [No Abstract]   [Full Text] [Related]  

  • 20. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
    Berry CN; Girard D; Lochot S; Lecoffre C
    Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.